Titan Pharmaceuticals

Titan Pharmaceuticals is a specialty pharmaceutical company developing treatments for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. Probuphine was approved by the U.S. Food and Drug Administration on May 26, 2016. Probuphine is the first commercially available product to provide continuous maintenance treatment for opioid addiction for six months following a single administration procedure.